非甾体抗炎药与抗血小板治疗对肝细胞癌发生及复发影响的系统综述与荟萃分析
结果显示阿司匹林降低HCC发生风险(HR 0.51,95%CI 0.36-0.72)并改善肝病相关死亡率(OR 0.32,95%CI 0.15-0.70),但轻微增加胃肠道出血风险(OR 1.32,95%CI 1.08-1.94);非阿司匹林NSAIDs与HCC复发风险降低相关(HR 0.73,95%CI 0.63-0.84)。
要点
- 阿司匹林可降低高危慢性肝病人群HCC发生风险并改善肝病相关死亡率。
- 非阿司匹林NSAIDs与HCC治疗后复发风险降低显著相关。
- 阿司匹林轻微增加胃肠道出血事件风险,需权衡获益与出血风险。
核心结论
- 研究支持在高危个体中使用阿司匹林以降低HCC发生率和肝病相关死亡率。
- NSAID治疗与HCC治疗后复发风险降低相关。
研究设计与样本
- 系统综述与荟萃分析,检索Pubmed、Scopus、Medline、Embase和Cochrane Library(建库至2021年5月31日)。
- 纳入标准为接受至少一种NSAID或抗血小板治疗 defined 时长并随访至少6个月,评估HCC发生率、复发、肝病相关死亡率或出血并发症。
主要发现
- 阿司匹林降低HCC发生风险(HR 0.51,95%CI 0.36-0.72)。
- 阿司匹林改善肝病相关死亡率(OR 0.32,95%CI 0.15-0.70)。
- 阿司匹林轻微增加胃肠道出血事件风险(OR 1.32,95%CI 1.08-1.94)。
- 所有阿司匹林和NSAID治疗与HCC复发风险降低相关(HR 0.80,95%CI 0.75-0.86)。
- 分层分析中仅非阿司匹林NSAID组显示显著复发风险降低(HR 0.73,95%CI 0.63-0.84)。
临床怎么用
- 对于慢性肝病高危患者,可考虑使用阿司匹林以降低HCC发生风险,但需评估胃肠道出血风险。
- 非阿司匹林NSAIDs可能有助于降低HCC治疗后复发风险,但需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chemoprevention with NSAIDs, including aspirin, and anti-platelet therapy (APT), has been suggested to reduce the incidence and recurrence of hepatocellular carcinoma (HCC). AIM: To determine by meta-analysis whether NSAIDs and APT use affected HCC incidence, HCC recurrence and liver-related mortality in at-risk populations with chronic liver disease. METHOD: Electronic databases including Pubmed, Scopus, Medline, Embase and Cochrane Library were searched (from inception to 31 May 2021) for eligible studies evaluating the impacts of NSAID or APT use on HCC incidence, recurrence and mortality. Data on HCC incidence, recurrence, liver-related mortality or bleeding complications had to be available. Studies were included if they evaluated adults with hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol-related liver disease (ALD) or nonalcoholic steatohepatitis that were administered at least one NSAID or APT for a defined period of time and were followed for at least 6 months. The primary outcome was HCC incidence. Secondary outcomes included: HCC recurrence, liver-related mortality and bleeding complications. Data were pooled using a random effects model with hazard ratios (HRs) or odds ratio (OR), and 95% confidence intervals (CIs) presented. RESULTS: Of 3773 articles screened, 19 studies were included, with a total of 147 283 participants. Aspirin use reduced the risk of HCC incidence (HR: 0.51, 95% CI: 0.36-0.72); and improved liver-related mortality (OR: 0.32, 95% CI: 0.15-0.70), with a small increased risk of gastrointestinal bleeding events (OR: 1.32, 95% CI: 1.08-1.94). With respect to HCC recurrence following treatment, analysis of all aspirin and NSAID treatment (including; aspirin only; non-aspirin NSAIDs only; and combination NSAIDs groups) was associated with a decreased risk of HCC recurrence (HR: 0.80, 95% CI: 0.75-0.86). By stratified analysis, only the non-aspirin NSAID group showed significant risk reduction (HR: 0.73, 95% CI: 0.63-0.84). CONCLUSION: The study supports the use of aspirin in at-risk individuals to reduce the incidence of HCC and liver-related mortality. HCC recurrence following treatment was lower with NSAID treatment.
引用
- Tan RZH, Lockart I, Abdel Shaheed C, et al. Systematic review with meta-analysis: The effects of non-steroidal anti-inflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma. Aliment Pharmacol Ther. 2021. PMID: 34247393. doi:10.1111/apt.16515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。